DFMO

(redirected from difluoromethylornithine)
AcronymDefinition
DFMODifluoromethylornithine
DFMODoppler Filter Mixer-Oscillator
DFMODance Floor Make-Out
DFMODivision Financial Management Office
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Pelot et al., "Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial," Cancer Prevention Research, vol.
Although preclinical studies showed promise for difluoromethylornithine (DFMO) (a competitive inhibitor of ODC) in the setting of BC, this has not been translated into positive results in human subjects.
Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice.
DFMO, or difluoromethylornithine, inhibits the synthesis of polyamines, basic compounds in cells.
Eflornithine (difluoromethylornithine) was developed in the 1970s and approved by the Food and Drug Administration (FDA) in 1990, but production was stopped in 1999.
Specialist treatment known as difluoromethylornithine (DFMO) aims to prevent relapse but is not available on the NHS.
Meyskens Jr., professor of medicine and biological chemistry at the University of California, Irvine, presented late-breaking results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), an NSAID, in 375 patients.
Cells were grown to confluence at which point they were treated with difluoromethylornithine (DFMO), diethylglyoxal bisguanylhydrazone (DEGBG), or a combination of the two.
Difluoromethylornithine, a drug to stop the growth of metastases, severely reduces platelet counts in the blood of cancer patients.
Meyskens Jr., professor of medicine and biological chemistry at the University of California, Irvine, presented "late-breaking" results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), a nonsteroidal, anti-inflammatory drug (NSAID), in 375 patients.
Currently under investigation are epigallocatechin gallate, a green tea catechin with antioxidant, sunscreen, and UVB signal transduction-blocking activity; perillyl alcohol, a monoterpene derived from citrus peel that inhibits Ras farnesylation; difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase and polyamines; retinoids that target retinoid X receptors and AP-1 activity; and nonsteroidal anti-inflammatory agents that inhibit cyclooxygenase and prostaglandin synthesis.